Pediatric Multiple Sclerosis—Experience of a Tertiary Care Center

Abstract

Background Pediatric-onset multiple sclerosis (POMS) accounts for 3 to 10% of all MS diagnoses. POMS is usually characterized by prominent disease activity, and patients are at higher risk of developing physical disability and cognitive impairment.

Objective This article characterizes a cohort of POMS patients followed at the pediatric neurology unit of a Portuguese tertiary hospital.

Methods Retrospective observational study. Clinical records of all patients with POMS between 2011 and 2020 were revised.

Results A total of 21 patients, with a female:male ratio of 11:10 and a mean age of onset of 14.8 years were included. Clinical manifestations at presentation included myelitis in eight patients (two with associated brainstem syndrome), optic neuritis in six (one with associated cerebellar syndrome), supratentorial symptoms in four, and isolated brainstem syndrome in two. Twenty patients had oligoclonal immunoglobulin G bands in cerebrospinal fluid. Supra- and infratentorial involvement was identified in the first brain magnetic resonance imaging of nine patients. Initial relapses were treated with intravenous steroids in 19 patients. The mean time for diagnosis was 2.8 months. Eleven patients were on first-line treatment (nine on β-interferon, two on teriflunomide) and 10 on second-line treatment (six on natalizumab, three on fingolimod, one on ocrelizumab). The mean annual relapse rate was 0.29 (range, 0.01–3), and the median Expanded Disability Status Scale was 1. Four patients reported learning disabilities and/or cognitive deficits.

Conclusion About half of patients in this cohort were on second-line disease-modifying treatment, with 19% showing cognitive impairment. Efforts to establish an early diagnosis are crucial to improving these patients' outcomes.

Keywords

adolescence - childhood - multiple sclerosis - neuroimmunology

Publication History

Received: 27 July 2022

Accepted: 05 November 2022

Article published online:
16 January 2023

• References

• 1 Deiva K. Pediatric onset multiple sclerosis. Rev Neurol (Paris) 2020; 176 (1-2): 30-36
• 2 Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6 (10) 887-902
• 3 Tenembaum S. Multiple sclerosis in childhood and adolescence. J Neurol Sci 2011; 311 (Suppl 1): S53-S57
• 4 Gordon-Lipkin E, Banwell B. An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future. Expert Rev Clin Immunol 2017; 13 (10) 975-989
• 5 Ness JM, Chabas D, Sadovnick AD, Pohl D, Banwell B, Weinstock-Guttman B. International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology 2007; 68 (16, Suppl 2): S37-S45
• 6 Thompson AJ, Banwell BL, Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17 (02) 162-173
• 7 Krupp LB, Tardieu M, Amato MP. et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
• 8 Mikaeloff Y, Suissa S, Vallée L. et al; KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004; 144 (02) 246-252
• 9 Gadoth N. Multiple sclerosis in children. Brain Dev 2003; 25 (04) 229-232
• 10 Hennes EM, Baumann M, Schanda K. et al; BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89 (09) 900-908
• 11 Fadda G, Brown RA, Longoni G. et al; Canadian Pediatric Demyelinating Disease Network. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2018; 2 (03) 191-204
• 12 Absoud M, Lim MJ, Chong WK. et al; UK and Ireland Childhood CNS Inflammatory Demyelination Working Group. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013; 19 (01) 76-86
• 13 Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 2004; 63 (10) 1966-1967
• 14 Boesen MS, Born AP, Jensen PEH. et al. Diagnostic value of oligoclonal bands in children: a nationwide population-based cohort study. Pediatr Neurol 2019; 97: 56-63
• 15 Rensel M. Long-term treatment strategies of pediatric multiple sclerosis, including the use of disease modifying therapies. Children (Basel) 2019; 6 (06) 73
• 16 Krysko KM, Graves J, Rensel M. et al; US Network of Pediatric MS Centers. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology 2018; 91 (19) e1778-e1787
• 17 Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines 2020; 8 (04) 71
• 18 Fernandes C, Durães J, Rodrigues F. et al. Pediatric multiple sclerosis before the PARADIGMS study: nine years of experience in a Portuguese tertiary center. Sinapse. 2021; 21 (01) 33-39
• 19 Correia AS, Augusto L, Meireles J, Pinto J, Sousa AP. Pediatric multiple sclerosis in Portugal: a multicentre study. Acta Med Port 2016; 29 (7-8): 425-431
• 20 Harding KE, Liang K, Cossburn MD. et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2013; 84 (02) 141-147
• 21 Hamdy SM, Abdel-Naseer M, Shalaby NM. et al. Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients. Neuropsychiatr Dis Treat 2018; 14: 631-640
• 22 Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012; 11 (10) 754-765
• 23 Hacohen Y, Brownlee W, Mankad K. et al. Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. Mult Scler J 2020; 26 (11) 1372-1380
• 24 Padilha IG, Fonseca APA, Pettengill ALM. et al. Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis. Pediatr Radiol 2020; 50 (06) 776-792
• 25 Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 1999; 21 (04) 279-282
• 26 Weinshenker B, Keegan B. Therapeutic plasma exchange for multiple sclerosis. Multiple Sclerosis Therapeutics, Third Edition. 2007. Taylor & Francis Group, informa healthcare; London: 551-565
• 27 Waldman A, Ness J, Pohl D. et al. Pediatric multiple sclerosis: clinical features and outcome. Neurology 2016; 87 (9, Suppl 2): S74-S81
• 28 Renoux C, Vukusic S, Mikaeloff Y. et al; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356 (25) 2603-2613
• 29 Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66 (01) 54-59
• 30 Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D. Pediatric multiple sclerosis: escalation and emerging treatments. Neurology 2016; 87 (9, Suppl 2): S103-S109
• 31 Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 2014; 13 (09) 936-948
• 32 McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology 2019; 92 (24) e2764-e2773